Photo from archive.org
For patients with recurring prostate cancer around 90% of relapses occur at the location of the primary tumor. That motivates further local dose escalation to avoid enhanced doses to rectum… Click to show full abstract
For patients with recurring prostate cancer around 90% of relapses occur at the location of the primary tumor. That motivates further local dose escalation to avoid enhanced doses to rectum and bladder. Boosting the dominant intraprostatic lesions (DIL) is currently explored in clinical studies. The purpose of this study was to assess the feasibility of DIL boosting with tomotherapy and to compare it dosimetrically to previously evaluated VMAT and IMPT strategies based on the same objectives [1].
Keywords:
vmat impt;
intraprostatic lesions;
physics;
dominant intraprostatic;
tomotherapy;
electronic poster
Journal Title: Radiotherapy and Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Radiotherapy and Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!